“Lebrikizumab Provides Stable Itch Response With No or Minimal Fluctuations up to One Year in Patients With Atopic Dermatitis”, J of Skin, vol. 7, no. 6, p. s282, Nov. 2023, doi: 10.25251/skin.7.supp.282.